((自动化翻译由路透提供，请见免责声明 ))
12月9日 - ** 抗皱注射剂生产商Revance Therapeutics 股价下跌20.9%，至3.02美元
** RVNC称私营护肤品公司Crown Laboratories将以每股3.10美元的价格全现金收购它 (link)
** 该交易的总股本价值约为 3.25 亿美元
** 8月份达成的最初协议是以每股6.66美元的价格收购RVNC。
** 在 Revance 于 9 月收到一份指控其违反 Teoxane独家分销协议的 通知后，收购价格被降低。
** 交易完成后，RVNC将成为一家私营公司
** 新交易较RVNC 12月6日的收盘价折价18.9
** 预计交易将于 2025 年第一季度完成
** 截至上次收盘，股价已累计下跌 56.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.